BIOLQ — November 26, Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- $12.94m
- $49.16m
- 19
- 63
- 37
- 33
Annual income statement for November 26,, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 37.8 | 22.8 | 39.2 | 48.5 | 49.2 |
| Cost of Revenue | |||||
| Gross Profit | 14.3 | 6.17 | 16.5 | 15.9 | 16.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 53.4 | 41.3 | 52.6 | 73.8 | 67.1 |
| Operating Profit | -15.6 | -18.5 | -13.4 | -25.3 | -17.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.9 | -16.7 | -16.1 | -28.5 | -20.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.9 | -16.8 | -16.2 | -28.6 | -20.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.9 | -16.8 | -16.2 | -28.6 | -20.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.9 | -34.2 | -16.7 | -28.9 | -37.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,924 | -1,399 | -312 | -416 | -29.4 |